Cardiff University | Prifysgol Caerdydd ORCA
Online Research @ Cardiff 
WelshClear Cookie - decide language by browser settings

A survey of healthcare professionals’ perceptions of GLP1 and GLP/GIP receptor agonist prescribing and monitoring in type 2 diabetes [Conference Abstract]

Brown, Freya, Davies, Helen and Bowen, Jenna ORCID: https://orcid.org/0000-0003-1964-6832 2026. A survey of healthcare professionals’ perceptions of GLP1 and GLP/GIP receptor agonist prescribing and monitoring in type 2 diabetes [Conference Abstract]. International Journal of Pharmacy Practice 34 (Supp 2) , ii58–ii59. 10.1093/ijpp/riag145.075

Full text not available from this repository.

Abstract

Introduction: Prior to the latest update, the National Institute for Health and Care Excellence (NICE) guidelines recommended Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) and Tirzepatide (a GLP/GIP Receptor Agonist) as part of a triple therapy regimen for uncontrolled Type 2 diabetes (T2DM) [1]. Locally, these medications are prescribed and reviewed as part of a primary care supplementary service. Previous NICE guidance also advised stopping GLP-1 RAs if weight and glycated haemoglobin (HbA1c) targets were not met within 6 months. However, a local audit identified that patients often remained on treatment despite not meeting these targets, depending on the healthcare professional (HCP) conducting the review. This variation could have unintended safety and economic implications. Aim: Explore healthcare professionals’ perceptions of prescribing and/or monitoring of GLP-1RAs and tirzepatide for T2DM in primary care. Method: An anonymous survey was designed using Microsoft Forms ® and electronically mailed to 42 HCPs identified as leads for the GLP-1 RA/tirzepatide supplementary service. The survey was distributed in November 2025, but recipients encouraged to forward the survey to other relevant practitioners as part of a snowball sampling approach. Participation was voluntary and informed consent obtained as part of the survey. All responses received prior to the communicated deadline in January 2026 were analysed using descriptive statistics via Microsoft Excel 360 ®. In questions where “other” was selected, individual responses were grouped into themes. Ethics approval was not required for this service evaluation, but local university and health board approval granted. Results: A total of 13 responses were received. The analysis revealed that all responding HCPs had reviewed patients within 0 to 6 months of initiating treatment with GLP-1 RAs or tirzepatide, however, mixed levels of confidence regarding treatment knowledge were reported. The perceived optimal prescribing duration was inconsistent amongst respondents. Factors recognised to influence treatment duration were patient comorbidities, HbA1c, weight values and patient tolerability. 92% (n=12) of respondents reported discontinuation due to adverse effects experienced by patients. All participants agreed that patients should receive lifestyle, dietary and educational support, with most respondents offering support at diagnosis and at every review. The responses highlighted the roles of multiple healthcare disciplines in providing T2DM support to patients, but the practice nurse consistently identified as playing an essential role. Discussion: This study suggests compliance with the NICE criteria recommended at the time. The respondents appeared to have found it challenging to standardise an optimal prescribing duration. NICE T2DM guidance has since been updated and the criteria for use and continuation amended, acknowledging benefits in early-onset T2DM, cardiovascular disease and obesity [2]. All participants agreed that lifestyle, dietary and educational support should be offered to patients with T2DM, demonstrating that primary care HCPs acknowledge the need for holistic approaches. All respondents agreed that practice nurses are essential in providing support, reflecting their core role in chronic disease management within primary care settings. The small sample size and likely self-selection and non-response bias are recognised limitations. Future work using qualitative interviews may provide richer insights.

Item Type: Short Communication
Date Type: Publication
Status: Published
Schools: Schools > Pharmacy
Publisher: Oxford University Press
ISSN: 0961-7671
Last Modified: 16 Nov 2026 13:00
URI: https://orca.cardiff.ac.uk/id/eprint/190956

Actions (repository staff only)

Edit Item Edit Item